NASDAQ: TTNPTitan Pharmaceuticals Inc Stock
$6.97-0.04 (-0.57%)
Updated Apr 24, 2024
TTNP Price
$6.97
Fair Value Price
$6.21
Market Cap
$6.37M
52 Week Low
$5.00
52 Week High
$16.60
P/E
-0.94x
P/B
0.96x
P/S
33.72x
PEG
N/A
Dividend Yield
N/A
Revenue
$184.00k
Earnings
-$5.57M
Gross Margin
100%
Operating Margin
-3,026.63%
Profit Margin
-3,026.6%
Debt to Equity
0.22
Operating Cash Flow
-$7M
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TTNP Overview
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TTNP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TTNP ($6.97) is overvalued by 12.29% relative to our estimate of its Fair Value price of $6.21 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TTNP ($6.97) is not significantly undervalued (12.29%) relative to our estimate of its Fair Value price of $6.21 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TTNP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TTNP due diligence checks available for Premium users.
Be the first to know about important TTNP news, forecast changes, insider trades & much more!
TTNP News
Valuation
TTNP fair value
Fair Value of TTNP stock based on Discounted Cash Flow (DCF)
Price
$6.97
Fair Value
$6.21
Overvalued by
12.29%
TTNP ($6.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TTNP ($6.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TTNP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TTNP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.94x
Industry
15.69x
Market
41.27x
TTNP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.96x
Industry
5.86x
TTNP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TTNP's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
TTNP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TTNP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$8.1M
Liabilities
$1.4M
Debt to equity
0.22
TTNP's short-term assets ($8.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TTNP's short-term assets ($8.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TTNP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TTNP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.2M
Investing
$504.0k
Financing
$406.0k
TTNP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TTNP vs Biotech Stocks
Titan Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.